While no universally accepted cutoff exists for IL-6, cohort studies have demonstrated that even modest elevations predict increased risk of cardiovascular and metabolic disease [57,58], suggesting that the reductions observed here may carry clinical significance. Here, IL6 is linked to metabolic disease.